| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | tanespimycin:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.0084 | 0.8 |
| mRNA | canertinib | CTRPv2 | pan-cancer | AAC | -0.0079 | 0.8 |
| mRNA | Nilotinib | CCLE | pan-cancer | AAC | 0.01 | 0.8 |
| mRNA | cabozantinib | CTRPv2 | pan-cancer | AAC | 0.0078 | 0.8 |
| mRNA | lapatinib | CTRPv2 | pan-cancer | AAC | 0.0076 | 0.8 |
| mRNA | LE-135 | CTRPv2 | pan-cancer | AAC | 0.0076 | 0.8 |
| mRNA | BRD-K07442505 | CTRPv2 | pan-cancer | AAC | -0.0078 | 0.8 |
| mRNA | myricetin | CTRPv2 | pan-cancer | AAC | 0.0079 | 0.8 |
| mRNA | HC-067047 | CTRPv2 | pan-cancer | AAC | -0.0078 | 0.8 |
| mRNA | OSI-027 | CTRPv2 | pan-cancer | AAC | 0.0071 | 0.8 |